Fatty acid 16:4(n-3) stimulates a GPR120-induced signaling cascade in splenic macrophages to promote chemotherapy resistance

FASEB Journal

Volumn 31, Issue 5, 2017, Pages 2195-2209

  Houthuijzen, Julia M ^a   Oosterom, Ilse ^b   Hudson, Brian D ^c   Hirasawa, Akira ^d   Daenen, Laura G M ^a   McLean, Chelsea M ^a   Hansen, Steffen V F ^e   Van Jaarsveld, Marijn T M ^a   Peeper, Daniel S ^a   Sadatmand, Sahar Jafari ^a   Roodhart, Jeanine M L ^b   Van De Lest, Chris H A ^f   Ulven, Trond ^e   Ishihara, Kenji ^g   Milligan, Graeme ^c   Voest, Emile E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d KYOTO UNIVERSITY   (Japan)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f UTRECHT UNIVERSITY   (Netherlands)

^g National Research Institute of Fisheries Science   (Japan)

Author keywords

FFAR1; FFAR4; GPR40; PIFA

Indexed keywords

1,2 DINERVONOYL PHOSPHATIDYLCHOLINE; ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CISPLATIN; CYTOSOLIC PHOSPHOLIPASE A2; FATTY ACID DERIVATIVE; G PROTEIN COUPLED RECEPTOR 120; HEXADECA 4,7,10,13 TETRAENOIC ACID; LYSOPHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; O3FAR1 PROTEIN, MOUSE; OMEGA 3 FATTY ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; LEWIS CARCINOMA; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN CELL; THERAPY RESISTANCE; ANIMAL; BAGG ALBINO MOUSE; DRUG RESISTANCE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DRUG RESISTANCE; FATTY ACIDS, OMEGA-3; MACROPHAGES; MICE, INBRED BALB C; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 85019459788     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.201601248R     Document Type: Article

References (37)

1. Briscoe,C.P.,Tadayyon,M.,Andrews, J.L., Benson,W.G.,Chambers, J. K., Eilert,M. M., Ellis, C., Elshourbagy, N. A., Goetz, A. S.,Minnick, D. T., Murdock, P. R., Sauls, H. R., Jr., Shabon, U., Spinage, L. D., Strum, J.C., Szekeres,P.G.,Tan,K.B.,Way, J.M., Ignar,D.M.,Wilson, S., and Muir, A. I. (2003) The orphan G protein-coupled receptor GPR40 is activated bymediumand long chain fatty acids. J. Biol. Chem. 278, 11303-11311
2. Milligan, G., Alvarez-Curto, E., Watterson, K. R., Ulven, T., and Hudson, B. D. (2015) Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/ FFA4. Br. J. Pharmacol. 172, 3254-3265
3. Briscoe, C. P., Peat,A. J., McKeown, S. C., Corbett, D. F., Goetz, A. S., Littleton, T. R.,McCoy, D. C., Kenakin, T. P., Andrews, J. L., Ammala, C., Fornwald, J. A., Ignar, D. M., and Jenkinson, S. (2006) Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br. J. Pharmacol. 148, 619-628
4. Ulven, T., and Christiansen, E. (2015) Dietary fatty acids and their potential for controlling metabolic diseases through activation of FFA4/GPR120. Annu. Rev. Nutr. 35, 239-263
5. Hirasawa, A., Tsumaya, K., Awaji, T., Katsuma, S., Adachi, T., Yamada, M., Sugimoto, Y., Miyazaki, S., and Tsujimoto, G. (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 11, 90-94
6. Oh, D. Y., Walenta, E., Akiyama, T. E., Lagakos, W. S., Lackey, D., Pessentheiner, A. R., Sasik, R., Hah, N., Chi, T. J., Cox, J. M., Powels, M.A., Di Salvo, J., Sinz,C.,Watkins, S.M.,Armando,A.M.,Chung,H., Evans,R.M.,Quehenberger,O.,McNelis, J.,Bogner-Strauss, J.G., and Olefsky, J. M. (2014) A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat. Med. 20, 942-947
7. Li,Z.,Qiu,Q.,Geng,X., Yang, J.,Huang,W., andQian,H. (2016)Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development. Expert Opin. Investig. Drugs 25, 871-890
8. Ichimura, A., Hirasawa, A., Poulain-Godefroy, O., Bonnefond, A., Hara, T., Yengo, L., Kimura, I., Leloire, A., Liu, N., Iida, K., Choquet, H., Besnard, P., Lecoeur, C., Vivequin, S., Ayukawa, K., Takeuchi, M., Ozawa, K.,Tauber, M.,Maffeis,C.,Morandi, A.,Buzzetti, R.,Elliott, P., Pouta, A., Jarvelin, M. R., Körner, A., Kiess, W., Pigeyre, M., Caiazzo, R., VanHul,W., VanGaal, L.,Horber, F.,Balkau, B., Lévy-Marchal,C., Rouskas, K., Kouvatsi, A., Hebebrand, J., Hinney, A., Scherag, A., Pattou, F.,Meyre, D., Koshimizu, T. A.,Wolowczuk, I., Tsujimoto, G., and Froguel, P. (2012) Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483, 350-354
9. Oh, D. Y., Talukdar, S.,Bae, E. J., Imamura, T.,Morinaga,H., Fan,W., Li,P., Lu,W. J.,Watkins,S.M., andOlefsky, J.M. (2010)GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142, 687-698
10. Liu, Y., Chen, L. Y., Sokolowska, M., Eberlein, M., Alsaaty, S., Martinez-Anton, A., Logun,C.,Qi,H. Y., and Shelhamer, J.H. (2014) The fish oil ingredient, docosahexaenoic acid, activates cytosolic phospholipase A2 via GPR120 receptor to produce prostaglandin E2 and plays an anti-inflammatory role inmacrophages. Immunology 143, 81-95
11. Gras, D.,Chanez, P.,Urbach,V.,Vachier, I.,Godard, P., andBonnans, C. (2009) Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor. Am. J. Physiol. Lung Cell. Mol. Physiol. 296, L970-L978
12. Mizuta, K., Zhang, Y.,Mizuta, F., Hoshijima, H., Shiga, T., Masaki, E., andEmala,C.W., Sr. (2015)Novel identification of the free fatty acid receptor FFAR1 that promotes contraction in airway smoothmuscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 309, L970-L982
13. Miyauchi, S., Hirasawa, A., Iga, T., Liu, N., Itsubo, C., Sadakane, K., Hara, T., and Tsujimoto, G. (2009) Distribution and regulation of protein expression of the free fatty acid receptor GPR120. Naunyn Schmiedebergs Arch. Pharmacol. 379, 427-434
14. Wauquier, F., Philippe, C., Léotoing, L., Mercier, S., Davicco, M. J., Lebecque, P., Guicheux, J., Pilet, P., Miot-Noirault, E., Poitout, V., Alquier, T., Coxam, V., and Wittrant, Y. (2013) The free fatty acid receptorGprotein-coupled receptor 40 (GPR40) protects frombone loss through inhibition of osteoclast differentiation. J. Biol. Chem. 288, 6542-6551
15. Gao, B., Huang,Q., Jie, Q., Lu, W. G.,Wang, L., Li, X. J., Sun, Z., Hu, Y. Q., Chen, L., Liu, B. H., Liu, J., Yang, L., and Luo, Z. J. (2015) GPR120: A bi-potential mediator to modulate the osteogenic and adipogenic differentiation of BMMSCs. Sci. Rep. 5, 14080
16. Wu, J. H., Micha, R., Imamura, F., Pan, A., Biggs, M. L., Ajaz, O., Djousse, L.,Hu, F. B., andMozaffarian,D. (2012)Omega-3 fatty acids and incident type 2 diabetes: a systematic review andmeta-analysis. Br. J. Nutr. 107, S214-S227
17. Colussi,G.,Catena, C.,Novello,M.,Bertin,N., andSechi, L. A. (2016) Impact of omega-3 polyunsaturated fatty acids on vascular function and blood pressure: relevance for cardiovascular outcomes. [E-pub ahead of print] Nutr. Metab. Cardiovasc. Dis.
18. Yore,M. M., Syed, I., Moraes-Vieira, P. M., Zhang,T., Herman, M. A., Homan, E. A., Patel, R. T., Lee, J., Chen, S., Peroni, O. D., Dhaneshwar, A. S., Hammarstedt, A., Smith, U., McGraw, T. E., Saghatelian, A., and Kahn, B. B. (2014) Discovery of a class of endogenous mammalian lipids with anti-diabetic and antiinflammatory effects. Cell 159, 318-332
19. Houthuijzen, J. M. (2016) For better or worse: FFAR1 and FFAR4 signaling in cancer and diabetes. Mol. Pharmacol. 90, 738-743
20. Hopkins,M.M., andMeier, K. E. (2016)Free fatty acidreceptors and cancer: from nutrition to pharmacology. [E-pub ahead of print] Handb. Exp. Pharmacol. doi: 10.1007/164-2016-48
21. Roodhart, J. M., Daenen, L. G., Stigter, E. C., Prins, H. J., Gerrits, J., Houthuijzen, J. M., Gerritsen, M. G., Schipper, H. S., Backer, M. J., van Amersfoort, M., Vermaat, J. S., Moerer, P., Ishihara, K., Kalkhoven, E., Beijnen, J. H., Derksen, P. W., Medema, R. H., Martens,A.C.,Brenkman,A.B., andVoest,E.E. (2011)Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 20, 370-383
22. Houthuijzen, J. M., Daenen, L. G., Roodhart, J. M., Oosterom, I., van Jaarsveld, M. T., Govaert, K. M., Smith, M. E., Sadatmand, S. J., Rosing, H., Kruse, F., Helms, B. J., van Rooijen, N., Beijnen, J. H., Haribabu, B., van de Lest, C. H., and Voest, E. E. (2014) Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response. Nat. Commun. 5, 5275
23. Ishihara, K., Murata, M., Kaneniwa, M., Saito, H., Komatsu, W., and Shinohara, K. (2000) Purification of stearidonic acid (18:4(n-3)) and hexadecatetraenoic acid (16:4(n-3)) from algal fatty acid with lipase and medium pressure liquid chromatography. Biosci. Biotechnol. Biochem. 64, 2454-2457
24. Sun, Q., Hirasawa, A., Hara, T., Kimura, I., Adachi, T., Awaji, T., Ishiguro, M., Suzuki, T., Miyata, N., and Tsujimoto, G. (2010) Structure-activity relationships of GPR120 agonists based on a docking simulation. Mol. Pharmacol. 78, 804-810
25. Shimpukade, B., Hudson, B. D., Hovgaard, C. K., Milligan, G., and Ulven, T. (2012) Discovery of a potent and selective GPR120 agonist. J. Med. Chem. 55, 4511-4515
26. Sparks, S. M., Chen, G., Collins, J. L., Danger, D., Dock, S. T., Jayawickreme, C., Jenkinson, S., Laudeman, C., Leesnitzer, M. A., Liang,X.,Maloney, P.,McCoy,D.C.,Moncol,D.,Rash,V., Rimele, T., Vulimiri, P., Way, J. M., and Ross, S. (2014) Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg. Med. Chem. Lett. 24, 3100-3103
27. Azevedo, C. M., Watterson, K. R., Wargent, E. T., Hansen, S. V., Hudson, B. D., Kȩpczyńska, M. A., Dunlop, J., Shimpukade, B., Christiansen,E., Milligan,G., Stocker,C. J., andUlven,T. (2016)Nonacidic free fatty acid receptor 4 agonists with antidiabetic activity. J. Med. Chem. 59, 8868-8878
28. Retra, K., Bleijerveld, O. B., van Gestel, R. A., Tielens, A. G., vanHellemond, J. J., andBrouwers, J. F. (2008)Asimple anduniversal method for the separation and identification of phospholipid molecular species. Rapid Commun. Mass Spectrom. 22, 1853-1862
29. Bolognini, D., Tobin, A. B., Milligan, G., and Moss, C. E. (2016) The pharmacology and function of receptors for short-chain fatty acids. Mol. Pharmacol. 89, 388-398
30. Hudson, B. D., Shimpukade, B., Mackenzie, A. E., Butcher, A. J., Pediani, J. D., Christiansen, E., Heathcote, H., Tobin, A. B., Ulven, T., and Milligan, G. (2013) The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism.Mol. Pharmacol. 84, 710-725
31. Hara, T., Hirasawa, A., Sun, Q., Sadakane, K., Itsubo, C., Iga, T., Adachi, T., Koshimizu, T. A., Hashimoto, T., Asakawa, Y., and Tsujimoto, G. (2009) Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch. Pharmacol. 380, 247-255
32. Davies,L. C., Jenkins,S. J., Allen, J. E., andTaylor,P. R. (2013)Tissueresident macrophages. Nat. Immunol. 14, 986-995
33. Wu,Q.,Wang,H., Zhao,X., Shi, Y., Jin,M.,Wan,B.,Xu,H.,Cheng, Y., Ge, H., and Zhang, Y. (2013) Identification of G-protein-coupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma. Oncogene 32, 5541-5550
34. Fukushima, K., Yamasaki, E., Ishii, S., Tomimatsu, A., Takahashi, K., Hirane, M., Fukushima, N., Honoki, K., and Tsujiuchi, T. (2015) Different roles of GPR120 and GPR40 in the acquisition ofmalignant properties in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 465, 512-515
35. Liu, Z., Hopkins, M. M., Zhang, Z., Quisenberry, C. B., Fix, L. C., Galvan, B. M., andMeier,K. E. (2015)Omega-3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells. J. Pharmacol. Exp. Ther. 352, 380-394
36. Schneider, G., Sellers, Z. P., Abdel-Latif, A., Morris, A. J., and Ratajczak, M. Z. (2014) Bioactive lipids, LPC and LPA, are novel prometastatic factors and their tissue levels increase in response to radio/chemotherapy. Mol. Cancer Res. 12, 1560-1573
37. Raynor, A., Jantscheff, P., Ross, T., Schlesinger,M.,Wilde,M.,Haasis, S., Dreckmann, T., Bendas, G., andMassing,U. (2015) Saturated and mono-unsaturated lysophosphatidylcholine metabolism in tumour cells: a potential therapeutic target for preventing metastases. Lipids Health Dis. 14, 69